drug
(estradiol + norethindrone acetate + relugolix)
Marketedupdated 3mo agoby Sumitomo Pharma America Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (estradiol + norethindrone acetate + relugolix)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 28, 2029
~2.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Nov 5, 2042formulationUS 12551447
- May 3, 2038method-of-use (U-2360)US 11793812
- Sep 29, 2037method-of-use (U-3129)US 11033551
- Sep 29, 2037method-of-use (U-3129)US 11957684
- Sep 27, 2033compositionUS 11795178
- Sep 27, 2033compositionUS 12325714
- Jan 28, 2029compositionUS 73009352.5y
- Jan 28, 2026compositionUS 8058280
FDA exclusivities (1)
- Jan 27, 2026M-289Method (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that